# Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors

> **NCT05382936** · PHASE1 · TERMINATED · sponsor: **Stemline Therapeutics, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SL-901

## Key facts

- **NCT ID:** NCT05382936
- **Lead sponsor:** Stemline Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-19
- **Primary completion:** 2023-05-05
- **Final completion:** 2023-05-05
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The study was stopped after careful consideration of the landscape of similar drugs and evolving standard of care.
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05382936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05382936, "Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05382936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*